Monte Rosa Reports $626M Cash, Advances Three Phase 2 Trials
GLUE has more than doubled off its 52-week low of $4.12.
Summary
Monte Rosa's Q2 update reveals a strong cash position of $626M, funding operations into 2029, and significant clinical progress. The GFORCE-1 study of MRT-8102 completed enrollment, with data readout expected in H2 2026, building on prior 85% CRP reduction data. Two Phase 2 trials are now active: MRT-2359 in prostate cancer and MRT-6160 in Sjögren's disease, the latter under the Novartis collaboration. The company plans to initiate three additional MRT-8102 Phase 2 studies over the next 9-12 months, targeting ASCVD, gout, and hidradenitis suppurativa. This follows a period of insider selling and a reduced institutional stake, but the clinical momentum and extended runway strengthen the investment thesis. Key catalysts include the GFORCE-1 readout and initial Phase 1/2 data for MRT-2359 by year-end.
At the time of this announcement, GLUE was trading at $15.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.12 to $25.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.